Patents by Inventor Markus G. Grutter

Markus G. Grutter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF PROKARYOTIC SPHINGOSINE-1-PHOSPHATE LYASES AND OF SPHINGOSINE-1-PHOSPHATE LYASES LACKING A TRANSMEMBRANE DOMAIN FOR TREATING HYPERPROLIFERATIVE AND OTHER DISEASES
    Publication number: 20130259851
    Abstract: The present invention relates to the use of prokaryotic sphingosine-1-phosphate lyases (S1PL) and S1PLs that lack a transmembrane domain or of a nucleic acid encoding such an S1PL in the prevention or treatment of a disease condition associated with elevated levels of sphingosine-1-phosphate (S1P), and for which S1P elevation is directly or indirectly causative. In addition, the invention relates to a new product in the form of S1PL lacking the N-terminal loop domain.
    Type: Application
    Filed: November 30, 2011
    Publication date: October 3, 2013
    Applicants: UNIVERSITAT ZURICH, UNIVERSITAT BERN
    Inventors: Uwe Zangemeister-Wittke, Andrea Huwiler, Markus G. Grutter, Florence Bourquin
  • Process for the manufacture of thrombin inhibitors
    Patent number: 5422249
    Abstract: The invention relates to DNA sequences that code for the amino acid sequence of the thrombin inhibitor hirudin, hybrid vectors containing such DNA sequences, host cells transformed with such hybrid vectors, novel polypeptides with thrombin-inhibiting activity produced from such transformed host cells, processes for the manufacture of these DNA sequences, hybrid vectors and transformed host cells, and processes for the manufacture of these thrombin-inhibitors using the transformed host cells. The hirudin compounds that can be produced according to the invention have valuable pharmacological properties.
    Type: Grant
    Filed: September 15, 1993
    Date of Patent: June 6, 1995
    Assignees: Ciba-Geigy Corporation, UCP Gen-Pharma AG
    Inventors: Manfred Liersch, Hans Rink, Walter Marki, Markus G. Grutter, Bernd Meyhack
  • DNA vector and recombinant host cell for production of hirullin P6 and P18
    Patent number: 5268296
    Abstract: Novel polypeptides, designated hirullins, have a strong antithrombic activity and can therefore be used for the therapy and prophylaxis of thromboses. Said compounds are isolated from the leech Hirudinaria manillensis or are produced by conventional peptide synthesis or by recombinant DNA techniques. DNA sequences encoding hirullins P6 and P18 are supplied, hybrid vectors and transformed microorganisms for recombinant hirullin production are supplied.
    Type: Grant
    Filed: February 21, 1992
    Date of Patent: December 7, 1993
    Assignees: Ciba-Geigy Corporation, UCP Gen-Pharma, AG
    Inventors: Reinhard Maschler, Verena Steiner, Markus G. Grutter
  • Genes encoding eglin C mutants
    Patent number: 5180667
    Abstract: DNA encoding novel eglin mutants that differ from the natural eglins B and C by the replacement of amino acids in the region of the active center (amino acid 45) by other amino acids are provided. The mutants, which are produced by recombinant genetic engineering, have valuable pharmacological properties.
    Type: Grant
    Filed: October 11, 1991
    Date of Patent: January 19, 1993
    Assignees: Ciba-Geigy Corporation, UCP Gen-Pharma, AG
    Inventors: Markus G. Grutter, Dirk Heinz, Manfred Liersch
  • Polypeptides with an anticoagulant activity
    Patent number: 5114922
    Abstract: Novel polypeptides, designated hirullins, have a strong antithrombic activity and can therefore be used for the therapy and prophylaxis of thromboses. Said compounds are isolated from the leech Hirudinaria manillensis or are produced by conventional peptide synthesis or by recombinant DNA techniques.
    Type: Grant
    Filed: June 8, 1989
    Date of Patent: May 19, 1992
    Assignees: Ciba-Geigy Corporation, UCP Gen-Pharma AG
    Inventors: Reinhard Maschler, Verena Steiner, Markus G. Grutter, Fritz Raschdorf
  • Modified eglin proteins
    Patent number: 5079229
    Abstract: Novel elgin mutants that differ from the natural eglins B and C by the replacement of one, two or three amino acids in the region of the active center (amino acids 45 and 46, Leu-Asp) by other amino acids are provided. The mutants, which can be produced by recombinant genetic engineering, have valuable pharmacological properties.
    Type: Grant
    Filed: March 7, 1989
    Date of Patent: January 7, 1992
    Assignee: Ciba-Geigy Corporation
    Inventors: Markus G. Grutter, Dirk Heinz, Manfred Liersch
  • Hybrid interferons
    Patent number: 5071761
    Abstract: Novel hybrid interferons are produced which are derived from lymphoblastoid interferons .alpha.-2 and .alpha.-3 belonging to the interferon .alpha.B and .alpha.D groups, respectively. The novel hybrid interferons possess valuable antiviral and antiproliferative properties.
    Type: Grant
    Filed: July 18, 1989
    Date of Patent: December 10, 1991
    Assignee: Ciba-Geigy Corporation
    Inventors: Francois Meyer, Albert Hinnen, Andreas Meister, Markus G. Grutter, Sefik Alkan
  • Hybrid interferons
    Patent number: 4885166
    Abstract: Novel hybrid interferons are produced which are derived from lymphoblastoid interferons .alpha.-2 and .alpha.-3 belonging to the interferon .alpha.B and .alpha.D groups, respectively. The novel hybrid interferons possess valuable antiviral and antiproliferative properties.
    Type: Grant
    Filed: June 5, 1986
    Date of Patent: December 5, 1989
    Assignee: Ciba-Geigy Corporation
    Inventors: Francois Meyer, Albert Hinnen, Andreas Meister, Markus G. Grutter, Sefik Alkan